NEW YORK – JP Morgan on Friday upgraded shares of Pacific Biosciences to an "Overweight" rating and increased its price target to $15 from $5.
A discussion with new PacBio CEO Christian Henry "provided an overview of the new strategy for the company going forward, leaving us encouraged about the abundant opportunities that lie ahead," JP Morgan Analyst Tycho Peterson wrote in a research note.